Cases & Deals

Bayer AG acquires Icon Genetics

Clients Bayer AG

Jones Day advised Bayer AG in the acquisition by its subsidiary Bayer Innovation GmbH of Icon Genetics AG from its founders and certain mostly state-owned venture capital funds. Icon Genetics discovers innovative methods for the development and use of engineered plants. Bayer Innovation evaluates and develops new fields of business for the Bayer Group that are in line with Bayer's core competencies of health care, nutrition and high-tech materials and complement its current key areas of innovation and business. Bayer and Icon Genetics had already cooperated on research projects prior to the transaction.

We use cookies to deliver our online services. Details of the cookies and other tracking technologies we use and instructions on how to disable them are set out in our Cookies Policy. By using this website you consent to our use of cookies.